TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ≥65 years of age at the time of consent~* Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2~* Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease~* Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study~* Previous clinical or microbiological diagnosis of COVID-19~* Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation~* Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Coadministration Group (Type: EXPERIMENTAL): Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
- 20vPnC-only Group (Type: ACTIVE_COMPARATOR): Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
- BNT162b2-only Group (Type: ACTIVE_COMPARATOR): Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females, 18 years of age or older at the start of the weight loss program.~* Subject has a BMI ≥ 25 kg/m2.~* Subject started a weight management program at the MWCC location on or after January 1, 2012.~* Subject followed the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for at least the first two weeks of their weight loss phase while an active member of the MWCC.~* Subject signed the Personal Health Information Consent Form.~Exclusion Criteria:~* Subject was concurrently following another weight loss program other than the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan while on that respective plan.~* Subject had documented use of prescription or over-the-counter weight loss pharmacotherapy (e.g., phentermine, Orlistat) concurrently with the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan.~* Subject completed initial consultation but did not participate in any follow-up visits.~* Subject is currently in the active weight loss phase of their program at the MWCC (Subjects in the transition or weight maintenance phases of their programs are eligible.)~* Written request by subject to revoke consent to use health information is present in subject chart.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 5 & 2 & 2 Plan (Type: None): MWCC members who used the Medifast 5 \& 2 \& 2 Meal Replacement Plan for weight loss.
- 4 & 2 & 1 Plan (Type: None): MWCC members who used the Medifast 4 \& 2 \& 1 Meal Replacement Plan for weight loss.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* anyone not excluded and consenting~Exclusion Criteria:~* contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin~* anyone seriously ill~* currently taking antimalarial medicines~* allergy to artemisinin drugs~* pregnant women in first trimester~* children under 3 months of age~* reported heart condition

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MDA with DHAp (Eurartesim) (Type: EXPERIMENTAL): All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
- Focal MDA with DHAp (Eurartesim) (Type: EXPERIMENTAL): All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
- Standard of Care (Control) (Type: NO_INTERVENTION): The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Probiotics Lactobacillus in the Management of Attention Deficit Hyperactive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 6 to 16 years old.~* Children fulfilled DSM(V) Criteria for ADHD syndrome.~Exclusion Criteria:~* Intelligence quotient (IQ) less than 80% .~* Presence of other medical conditions as chronic medical or neuropsychiatric disorders e.g diabetes mellitus, epilepsy.....etc. hearing or visual impairment, or medications side effects.~* currently taking probiotics or antibiotics

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Patient with attention deficit hyperactive disorser (Type: ACTIVE_COMPARATOR): patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks added to standard treatment
- ADHD not receiving probiotics (Type: NO_INTERVENTION): ADHD patient (40) on standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: spontaneous or inducible ventricular tachycardia or fibrillation -~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Severe or moderately severe hemophilia A (baseline Factor VIII (FVIII) ≤ 2%)~* ≤12 years of age~* Participant's legally authorized representative(s) has provided written informed consent~* Participant is prescribed ADVATE and will only receive ADVATE reconstituted in 2 mL sterile water for injection (SWFI)~* Documented history of prior exposure to ADVATE~* Documented evidence of negative inhibitor test result during ≤10 EDs prior to study entry~Exclusion Criteria:~* Known hypersensitivity to the active substance or to any of the excipients~* Known allergic reaction to mouse or hamster proteins~* Participant has a requirement for a major surgical procedure at the time of enrollment~* Participant has no prior exposure to a FVIII concentrate~* Participant currently being treated with an immune tolerance induction (ITI) regimen~* Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (eg, qualitative platelet defect or von Willebrand disease)~* Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device or PASS registry during the course of this study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- ADVATE - 2mL (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with moderate to severe RA who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab according to his/her clinical judgment and the conditions approved in the Summary of Product Characteristics (SPC).~Exclusion Criteria:~* Participants previously or currently treated with RoActemra/Actemra in clinical trials~* Absolute neutrophil count less than or equal to (\</=) 2x10\^9 per liter (/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rheumatoid Arthritis Participants (Type: None): Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BlueSync Field Evaluation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient will be/has been implanted with an Azure™ or Percepta™, Serena™, Solara™ CRT-P device compatible with BlueSync™ (both new and replacement devices are allowed)~* Patient must own a smart device (Smartphone or tablet) that meets system requirements and be willing to use during evaluation period~* Patient must be able to complete the required 12-month follow-up after enrollment~* Patients must be of legal age according to local law~Exclusion Criteria:~* Patient unwilling to complete required surveys during 12-month evaluation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evaluation Group (Type: None): Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
- Control Group (Type: None): Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is diagnosed with bipolar I disorder, most resent episode depressed~* Subject must have a lifetime history of at least one bipolar manic or mixed episode~Exclusion Criteria:~* History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode~* Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization~* Imminent risk of suicide or injury to self, others, or property

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- lurasidone low arm (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- lurasidone high arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive~* Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine)~* Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening. If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or emtricitabine must have been stopped at least 12 weeks prior to screening~* Documented hepatitis B virus DNA (HBV DNA) \< 400 copies/mL for at least 3.5 years prior to screening and at screening~* ALT within normal range~* α-fetoprotein (AFP) \<= 50 ng/mL~* Calculated creatinine clearance \>= 70 mL/min by Cockcroft-Gault formula using ideal body weight~* \<= 10 kPa on Fibroscan assessment~* A negative serum pregnancy test for female subjects~* Adult subjects \>= 18 years of age~Key Exclusion Criteria:~* Known cirrhosis~* Evidence of fibrosis \>= Stage 3 (METAVIR) on liver biopsy or Fibroscan \> 10 kPa within 6 months prior to screening~* Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA \> 400 copies/mL within 3.5 years prior to screening~* History of decompensated liver disease (defined as direct \[conjugated\] bilirubin \> 1.5 x upper limit of normal, prothrombin time (PT) \> 1.5 x upper limit of normal, platelets \< 75,000/mm³, serum albumin \< 3.0 g/dL~* History of clinical hepatic decompensation in the judgement of the investigator~* Evidence of hepatocellular carcinoma~* Significant bone disease (in the judgment of the investigator)~* Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection~* Known hypersensitivity to TDF, its metabolites, or formulation excipients~* Concomitant therapy with disallowed medications~* History of malignant disease~* Lactating females~* Females wishing to became pregnant during the duration of the stud~* Subjects participating in another clinical trial can only be enrolled at the discretion of the Medical Monitor~Note: Other protocol defined inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stop TDF (Type: EXPERIMENTAL): Participants randomized to this arm will stop TDF therapy at baseline.
- Continue TDF (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will continue TDF therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The Test Group will be patients with rheumatoid arthritis, newly starting therapy with etanercept (Enbrel). Inclusion criteria for the exposed cohort subjects are:~* Patients aged 18 years and over at the time of diagnosis;~* Patients from the BSRBR with moderate RA as defined by a DAS28 (\>3.2 and ≤5.1);~* Patients who have given informed consent for long term follow-up and access to all medical records;~* Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel) for RA.~The Control Group:~* Patients aged 18 years and over a the time of diagnosis;~* Patients from the BSRBR with moderate RA as defined by a DAS28 (\>3.2 and ≤5.1);~* Patients who have given informed consent for long term follow-up and access to all medical records; Patients are receiving at least one traditional DMARD and have never been prescribed a biologic agent;~Exclusion Criteria:~Per BSRBR registry since data is retropsectively being analyzed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biologic (Type: None): None
- non-biologic DMARD (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of Autistic Disorder (299.00)~* ABC-I Subscale score of greater than or equal to 18~* CGI-S of greater than or equal to 4~* mental age \>18 months, body weight of at least 20 kg, seizure-free for at least 6 consecutive months and if on anticonvulsants must be on a dosage that has been stable for at least 4 weeks~* Medication free for 1 week before the start of the study for all psychotropic drugs, except 4 weeks for fluoxetine and at least 8 weeks for injectable medications~* Female patients must be premenarchal or sexually abstinent or, if heterosexually active, must practice an effective method of birth control.~Exclusion Criteria:~* History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's~* Any history of hypersensitivity to risperidone, or its excipients in formulation, or other known drug allergy~* Patients who received risperidone within 3 months before screening (except p.r.n. use)~* Patients who did not demonstrate sufficient clinical response to an adequate trial of risperidone treatment in the past (an adequate trial is defined as a period of at least 4 weeks at an adequate dose)~* Neurologic disorder (e.g., Neuroleptic Malignant Syndrome, seizure disorders that are unstable, seizure activity within the past 6 months)~* History of alcohol or substance dependence within 3 months of screening~* Female subject who is pregnant (positive beta-HCG) or breast feeding~* Patients with existing moderate or severe EPS or history of tardive dyskinesia~* Patients who have received an experimental drug or used an experimental medical device within 3 months before the planned start of treatment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Risperidone low dose Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
- 002 (Type: EXPERIMENTAL): Risperidone high dose Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo Oral solution qd or bid for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete